Mackenzie Financial Corp boosted its position in DaVita Inc. (NYSE:DVA - Free Report) by 116.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,931 shares of the company's stock after purchasing an additional 4,267 shares during the quarter. Mackenzie Financial Corp's holdings in DaVita were worth $1,186,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. raised its position in shares of DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after purchasing an additional 275,284 shares during the last quarter. Northern Trust Corp lifted its stake in shares of DaVita by 12.5% in the 4th quarter. Northern Trust Corp now owns 740,774 shares of the company's stock worth $110,783,000 after purchasing an additional 82,326 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of DaVita by 14.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock worth $69,697,000 after buying an additional 57,386 shares during the last quarter. Amundi grew its position in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the period. Finally, Deutsche Bank AG increased its holdings in DaVita by 35.2% during the fourth quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock valued at $58,687,000 after buying an additional 102,230 shares during the last quarter. Institutional investors own 90.12% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently issued reports on DVA. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Finally, Truist Financial dropped their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $164.50.
Read Our Latest Research Report on DVA
DaVita Stock Up 0.6%
Shares of DVA traded up $0.84 during midday trading on Wednesday, hitting $136.83. 721,412 shares of the company's stock traded hands, compared to its average volume of 821,654. DaVita Inc. has a 1 year low of $131.76 and a 1 year high of $179.60. The firm's fifty day moving average is $143.15 and its 200-day moving average is $152.40. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The stock has a market capitalization of $10.33 billion, a price-to-earnings ratio of 12.74, a price-to-earnings-growth ratio of 1.07 and a beta of 1.11.
DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The business had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the previous year, the firm posted $2.26 earnings per share. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
